

Discover the Elements
of TREANDA® Monotherapy

TREANDA®
(bendamustine HCl)
for Injection
Built for Action™



CLL:

TREANDA® superiority over chlorambucil: 1

2.6 times greater median PFS

2x greater ORR

2x longer DOR

NHL:

Meaningful & enduring 2nd-line responses:

88% ORR in patients sensitive to their last chemotherapy regimen

64% ORR in patients who are refractory to their last chemotherapy regimen

9.3 months median PFS

9.2 months median DOR

Discover how you can make a difference to your patients

More information is available upon request

CLL=chronic lymphocytic leukaemia. PFS=progression-free survival. ORR=overall response rate. DOR=duration of response. NHL=non-Hodgkin's lymphoma.

teva

Further information is available on request
Teva Pharmaceutical Hong Kong Limited
Room 2303, 23/F., Mira Place Tower A, 132 Nathan Road,
Tsim Sha Tsui, Kowloon, Hong Kong.
Tel: +852 3168 4288 Fax: +852 3585 6220

References

1. B. Van der Jagt, et al. Current Oncology Vol 19, Number 3, June 2012
2. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010;116:106-114.